Novartis's secukinumab outscores Enbrel in psoriasis FIXTURE
This article was originally published in Scrip
Executive Summary
Targeting interleukin 17 (IL-17) is looking a promising new avenue of treatment in psoriasis following positive top-line data for Novartis's secukinumab in a Phase III head-to-head study against Amgen/Pfizer's Enbrel (etanercept).